MetLife Investment Management LLC Sells 1,550 Shares of Illumina, Inc. (NASDAQ:ILMN)

MetLife Investment Management LLC lessened its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 82,335 shares of the life sciences company’s stock after selling 1,550 shares during the period. MetLife Investment Management LLC’s holdings in Illumina were worth $10,737,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Primecap Management Co. CA raised its position in Illumina by 462.5% during the second quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock valued at $253,514,000 after purchasing an additional 1,997,010 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Illumina by 305.0% during the 2nd quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock worth $155,067,000 after buying an additional 1,118,747 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Illumina during the 2nd quarter worth $77,628,000. Massachusetts Financial Services Co. MA boosted its stake in Illumina by 148.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,056,172 shares of the life sciences company’s stock valued at $137,735,000 after buying an additional 631,294 shares in the last quarter. Finally, Federated Hermes Inc. grew its position in Illumina by 511.7% in the second quarter. Federated Hermes Inc. now owns 530,439 shares of the life sciences company’s stock valued at $55,367,000 after acquiring an additional 443,720 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Up 1.0 %

Shares of Illumina stock opened at $144.36 on Friday. The stock’s 50-day moving average is $141.62 and its 200 day moving average is $125.66. Illumina, Inc. has a one year low of $93.51 and a one year high of $156.66. The firm has a market cap of $22.90 billion, a price-to-earnings ratio of -14.49 and a beta of 1.13. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.33 EPS. Equities research analysts anticipate that Illumina, Inc. will post 4.11 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Citigroup increased their target price on shares of Illumina from $155.00 to $190.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. HSBC upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a research report on Thursday, October 17th. Barclays boosted their target price on shares of Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. increased their price target on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Finally, StockNews.com started coverage on Illumina in a research report on Thursday, August 29th. They set a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $164.00.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.